Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

Summary

The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.

Eligibility

Inclusion Criteria:

* hematologic malignancy patients
* patients eligible for the transplantation of allogeneic hematopoietic stem cells;
* patients unavailable with HLA matched donor or related haploidentical donor
* voluntary participation in this study and signing the informed consent form.

Exclusion Criteria:

* Patients with the severe infections;
* Pregnant or lactating women
* Patients who are not eligible for hematopoietic stem cell transplantation;
* Patients who are enrolled in other clinical trials within 1 month;
* Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study;
* Patients unable to properly understand or refusing to accept the informed consent form.

Conditions3

Browse More Trials